Morgan Stanley issued a technical opinion report, it is believed that the share price of Tongrentang National Pharmaceutical (03613.HK) will rise within 30 days, and the probability is expected to be 70% to 80%. Give it a "overweight" rating, with a target price of 16.50 yuan.
Daimo Index, the mainland recently issued the "Development Plan for promoting the Integration of High quality Chinese Medicine into the Co-Construction of Belt and Road Initiative (2021-2025)", calling for the wider application of Chinese medicine in countries along the Belt and Road, although at present, it is largely a verbal appeal, but the policy stance is expected to boost stock sentiment towards Tongrentang Sinopharmaceuticals. Among the three listed companies in Tongrentang, Tongrentang Sinopharmaceuticals is responsible for developing overseas markets. As of the first half of 2021, its 69 retail outlets covered 20 countries in Europe, North America, Southeast Asia and Oceania.